The Cancer Letter

Inside information on cancer research and drug development

Vol.
24
No.
36
September 25, 1998Sep 25, 1998
Free
DOWNLOAD THE PDF

Experts Say Interpretable Results Unlikely In Burzynski’s Antineoplastons Studies

Special Report: Politicla Pressure, System Loopholes, Enabled Burzynski To Avoid Usuals

Scientific Process

“Unfortunate Result Of Burzynski’s Practice Over Two Decades: Thousands Of Patients, Not Enough Data” To Determine Safety, Efficacy, FDA Says

Reviewers Note Major Flaws In Design Of Burzynski’s Trials

Interview: Burzynski Explains Why He Calls Treatment “Non-Toxic”

Case Study: The Post-Surgical Treatment Of A Child With Medulloblastoma At The Burzynski Clinic

Login

Site license subscribers:
Log in with your IP | Register a sponsored account